Medical Care
Global Next Generation Antibody Therapeutics Market Research Report 2025
- Mar 24, 25
- ID: 10075
- Pages: 87
- Figures: 88
- Views: 49
The global market for Next Generation Antibody Therapeutics was valued at US$ 14630 million in the year 2024 and is projected to reach a revised size of US$ 51550 million by 2031, growing at a CAGR of 20.0% during the forecast period.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions.
In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %.
This report aims to provide a comprehensive presentation of the global market for Next Generation Antibody Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Antibody Therapeutics.
The Next Generation Antibody Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next Generation Antibody Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next Generation Antibody Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics
Segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions.
In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %.
This report aims to provide a comprehensive presentation of the global market for Next Generation Antibody Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Antibody Therapeutics.
The Next Generation Antibody Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next Generation Antibody Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next Generation Antibody Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics
Segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody Drug Conjugate (ADC)
1.2.3 Bispecific Antibody (BsAb)
1.3 Market by Application
1.3.1 Global Next Generation Antibody Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2020-2031)
2.2 Global Next Generation Antibody Therapeutics Growth Trends by Region
2.2.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Next Generation Antibody Therapeutics Market Dynamics
2.3.1 Next Generation Antibody Therapeutics Industry Trends
2.3.2 Next Generation Antibody Therapeutics Market Drivers
2.3.3 Next Generation Antibody Therapeutics Market Challenges
2.3.4 Next Generation Antibody Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next Generation Antibody Therapeutics Revenue
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2024
3.5 Global Key Players of Next Generation Antibody Therapeutics Head office and Area Served
3.6 Global Key Players of Next Generation Antibody Therapeutics, Product and Application
3.7 Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Antibody Therapeutics Breakdown Data by Type
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2026-2031)
5 Next Generation Antibody Therapeutics Breakdown Data by Application
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next Generation Antibody Therapeutics Market Size (2020-2031)
6.2 North America Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
6.4 North America Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Market Size (2020-2031)
7.2 Europe Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next Generation Antibody Therapeutics Market Size (2020-2031)
9.2 Latin America Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Next Generation Antibody Therapeutics Introduction
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Next Generation Antibody Therapeutics Introduction
11.3.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Next Generation Antibody Therapeutics Introduction
11.4.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Details
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.5.5 Daiichi Sankyo Recent Development
11.6 Seagen
11.6.1 Seagen Company Details
11.6.2 Seagen Business Overview
11.6.3 Seagen Next Generation Antibody Therapeutics Introduction
11.6.4 Seagen Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.6.5 Seagen Recent Development
11.7 Astellas
11.7.1 Astellas Company Details
11.7.2 Astellas Business Overview
11.7.3 Astellas Next Generation Antibody Therapeutics Introduction
11.7.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.7.5 Astellas Recent Development
11.8 Immunomedics
11.8.1 Immunomedics Company Details
11.8.2 Immunomedics Business Overview
11.8.3 Immunomedics Next Generation Antibody Therapeutics Introduction
11.8.4 Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.8.5 Immunomedics Recent Development
11.9 GSK
11.9.1 GSK Company Details
11.9.2 GSK Business Overview
11.9.3 GSK Next Generation Antibody Therapeutics Introduction
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.9.5 GSK Recent Development
11.10 Immunocore
11.10.1 Immunocore Company Details
11.10.2 Immunocore Business Overview
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.10.5 Immunocore Recent Development
11.11 ADC Therapeutics
11.11.1 ADC Therapeutics Company Details
11.11.2 ADC Therapeutics Business Overview
11.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Introduction
11.11.4 ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.11.5 ADC Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody Drug Conjugate (ADC)
1.2.3 Bispecific Antibody (BsAb)
1.3 Market by Application
1.3.1 Global Next Generation Antibody Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2020-2031)
2.2 Global Next Generation Antibody Therapeutics Growth Trends by Region
2.2.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Next Generation Antibody Therapeutics Market Dynamics
2.3.1 Next Generation Antibody Therapeutics Industry Trends
2.3.2 Next Generation Antibody Therapeutics Market Drivers
2.3.3 Next Generation Antibody Therapeutics Market Challenges
2.3.4 Next Generation Antibody Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next Generation Antibody Therapeutics Revenue
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2024
3.5 Global Key Players of Next Generation Antibody Therapeutics Head office and Area Served
3.6 Global Key Players of Next Generation Antibody Therapeutics, Product and Application
3.7 Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Antibody Therapeutics Breakdown Data by Type
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2026-2031)
5 Next Generation Antibody Therapeutics Breakdown Data by Application
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next Generation Antibody Therapeutics Market Size (2020-2031)
6.2 North America Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
6.4 North America Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Market Size (2020-2031)
7.2 Europe Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next Generation Antibody Therapeutics Market Size (2020-2031)
9.2 Latin America Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Next Generation Antibody Therapeutics Introduction
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Next Generation Antibody Therapeutics Introduction
11.3.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Next Generation Antibody Therapeutics Introduction
11.4.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Details
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.5.5 Daiichi Sankyo Recent Development
11.6 Seagen
11.6.1 Seagen Company Details
11.6.2 Seagen Business Overview
11.6.3 Seagen Next Generation Antibody Therapeutics Introduction
11.6.4 Seagen Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.6.5 Seagen Recent Development
11.7 Astellas
11.7.1 Astellas Company Details
11.7.2 Astellas Business Overview
11.7.3 Astellas Next Generation Antibody Therapeutics Introduction
11.7.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.7.5 Astellas Recent Development
11.8 Immunomedics
11.8.1 Immunomedics Company Details
11.8.2 Immunomedics Business Overview
11.8.3 Immunomedics Next Generation Antibody Therapeutics Introduction
11.8.4 Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.8.5 Immunomedics Recent Development
11.9 GSK
11.9.1 GSK Company Details
11.9.2 GSK Business Overview
11.9.3 GSK Next Generation Antibody Therapeutics Introduction
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.9.5 GSK Recent Development
11.10 Immunocore
11.10.1 Immunocore Company Details
11.10.2 Immunocore Business Overview
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.10.5 Immunocore Recent Development
11.11 ADC Therapeutics
11.11.1 ADC Therapeutics Company Details
11.11.2 ADC Therapeutics Business Overview
11.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Introduction
11.11.4 ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
11.11.5 ADC Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antibody Drug Conjugate (ADC)
Table 3. Key Players of Bispecific Antibody (BsAb)
Table 4. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Next Generation Antibody Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Next Generation Antibody Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Next Generation Antibody Therapeutics Market Share by Region (2020-2025)
Table 8. Global Next Generation Antibody Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Next Generation Antibody Therapeutics Market Share by Region (2026-2031)
Table 10. Next Generation Antibody Therapeutics Market Trends
Table 11. Next Generation Antibody Therapeutics Market Drivers
Table 12. Next Generation Antibody Therapeutics Market Challenges
Table 13. Next Generation Antibody Therapeutics Market Restraints
Table 14. Global Next Generation Antibody Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Next Generation Antibody Therapeutics Market Share by Players (2020-2025)
Table 16. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2024)
Table 17. Ranking of Global Top Next Generation Antibody Therapeutics Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Next Generation Antibody Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Next Generation Antibody Therapeutics, Headquarters and Area Served
Table 20. Global Key Players of Next Generation Antibody Therapeutics, Product and Application
Table 21. Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2020-2025)
Table 25. Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2026-2031)
Table 27. Global Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2020-2025)
Table 29. Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2026-2031)
Table 31. North America Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Next Generation Antibody Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Roche Company Details
Table 47. Roche Business Overview
Table 48. Roche Next Generation Antibody Therapeutics Product
Table 49. Roche Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Amgen Company Details
Table 52. Amgen Business Overview
Table 53. Amgen Next Generation Antibody Therapeutics Product
Table 54. Amgen Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 55. Amgen Recent Development
Table 56. Pfizer Company Details
Table 57. Pfizer Business Overview
Table 58. Pfizer Next Generation Antibody Therapeutics Product
Table 59. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. Takeda Company Details
Table 62. Takeda Business Overview
Table 63. Takeda Next Generation Antibody Therapeutics Product
Table 64. Takeda Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Takeda Recent Development
Table 66. Daiichi Sankyo Company Details
Table 67. Daiichi Sankyo Business Overview
Table 68. Daiichi Sankyo Next Generation Antibody Therapeutics Product
Table 69. Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Daiichi Sankyo Recent Development
Table 71. Seagen Company Details
Table 72. Seagen Business Overview
Table 73. Seagen Next Generation Antibody Therapeutics Product
Table 74. Seagen Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Seagen Recent Development
Table 76. Astellas Company Details
Table 77. Astellas Business Overview
Table 78. Astellas Next Generation Antibody Therapeutics Product
Table 79. Astellas Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Astellas Recent Development
Table 81. Immunomedics Company Details
Table 82. Immunomedics Business Overview
Table 83. Immunomedics Next Generation Antibody Therapeutics Product
Table 84. Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Immunomedics Recent Development
Table 86. GSK Company Details
Table 87. GSK Business Overview
Table 88. GSK Next Generation Antibody Therapeutics Product
Table 89. GSK Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 90. GSK Recent Development
Table 91. Immunocore Company Details
Table 92. Immunocore Business Overview
Table 93. Immunocore Next Generation Antibody Therapeutics Product
Table 94. Immunocore Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Immunocore Recent Development
Table 96. ADC Therapeutics Company Details
Table 97. ADC Therapeutics Business Overview
Table 98. ADC Therapeutics Next Generation Antibody Therapeutics Product
Table 99. ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 100. ADC Therapeutics Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
Table 104. Authors List of This Report
List of Figures
Figure 1. Next Generation Antibody Therapeutics Picture
Figure 2. Global Next Generation Antibody Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Next Generation Antibody Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Antibody Drug Conjugate (ADC) Features
Figure 5. Bispecific Antibody (BsAb) Features
Figure 6. Global Next Generation Antibody Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Next Generation Antibody Therapeutics Market Share by Application: 2024 VS 2031
Figure 8. Cancer Case Studies
Figure 9. Haemophilia Case Studies
Figure 10. Other Non-Cancer Diseases Case Studies
Figure 11. Next Generation Antibody Therapeutics Report Years Considered
Figure 12. Global Next Generation Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Next Generation Antibody Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Next Generation Antibody Therapeutics Market Share by Region: 2024 VS 2031
Figure 15. Global Next Generation Antibody Therapeutics Market Share by Players in 2024
Figure 16. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 2024
Figure 18. North America Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 20. United States Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 24. Germany Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Region (2020-2031)
Figure 32. China Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 40. Mexico Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 44. Turkey Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Roche Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 48. Amgen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 49. Pfizer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 50. Takeda Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 51. Daiichi Sankyo Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 52. Seagen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 53. Astellas Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 54. Immunomedics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 55. GSK Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 56. Immunocore Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 57. ADC Therapeutics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antibody Drug Conjugate (ADC)
Table 3. Key Players of Bispecific Antibody (BsAb)
Table 4. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Next Generation Antibody Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Next Generation Antibody Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Next Generation Antibody Therapeutics Market Share by Region (2020-2025)
Table 8. Global Next Generation Antibody Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Next Generation Antibody Therapeutics Market Share by Region (2026-2031)
Table 10. Next Generation Antibody Therapeutics Market Trends
Table 11. Next Generation Antibody Therapeutics Market Drivers
Table 12. Next Generation Antibody Therapeutics Market Challenges
Table 13. Next Generation Antibody Therapeutics Market Restraints
Table 14. Global Next Generation Antibody Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Next Generation Antibody Therapeutics Market Share by Players (2020-2025)
Table 16. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2024)
Table 17. Ranking of Global Top Next Generation Antibody Therapeutics Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Next Generation Antibody Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Next Generation Antibody Therapeutics, Headquarters and Area Served
Table 20. Global Key Players of Next Generation Antibody Therapeutics, Product and Application
Table 21. Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2020-2025)
Table 25. Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2026-2031)
Table 27. Global Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2020-2025)
Table 29. Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2026-2031)
Table 31. North America Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Next Generation Antibody Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Next Generation Antibody Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Roche Company Details
Table 47. Roche Business Overview
Table 48. Roche Next Generation Antibody Therapeutics Product
Table 49. Roche Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Amgen Company Details
Table 52. Amgen Business Overview
Table 53. Amgen Next Generation Antibody Therapeutics Product
Table 54. Amgen Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 55. Amgen Recent Development
Table 56. Pfizer Company Details
Table 57. Pfizer Business Overview
Table 58. Pfizer Next Generation Antibody Therapeutics Product
Table 59. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. Takeda Company Details
Table 62. Takeda Business Overview
Table 63. Takeda Next Generation Antibody Therapeutics Product
Table 64. Takeda Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Takeda Recent Development
Table 66. Daiichi Sankyo Company Details
Table 67. Daiichi Sankyo Business Overview
Table 68. Daiichi Sankyo Next Generation Antibody Therapeutics Product
Table 69. Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Daiichi Sankyo Recent Development
Table 71. Seagen Company Details
Table 72. Seagen Business Overview
Table 73. Seagen Next Generation Antibody Therapeutics Product
Table 74. Seagen Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Seagen Recent Development
Table 76. Astellas Company Details
Table 77. Astellas Business Overview
Table 78. Astellas Next Generation Antibody Therapeutics Product
Table 79. Astellas Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Astellas Recent Development
Table 81. Immunomedics Company Details
Table 82. Immunomedics Business Overview
Table 83. Immunomedics Next Generation Antibody Therapeutics Product
Table 84. Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Immunomedics Recent Development
Table 86. GSK Company Details
Table 87. GSK Business Overview
Table 88. GSK Next Generation Antibody Therapeutics Product
Table 89. GSK Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 90. GSK Recent Development
Table 91. Immunocore Company Details
Table 92. Immunocore Business Overview
Table 93. Immunocore Next Generation Antibody Therapeutics Product
Table 94. Immunocore Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Immunocore Recent Development
Table 96. ADC Therapeutics Company Details
Table 97. ADC Therapeutics Business Overview
Table 98. ADC Therapeutics Next Generation Antibody Therapeutics Product
Table 99. ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 100. ADC Therapeutics Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
Table 104. Authors List of This Report
List of Figures
Figure 1. Next Generation Antibody Therapeutics Picture
Figure 2. Global Next Generation Antibody Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Next Generation Antibody Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Antibody Drug Conjugate (ADC) Features
Figure 5. Bispecific Antibody (BsAb) Features
Figure 6. Global Next Generation Antibody Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Next Generation Antibody Therapeutics Market Share by Application: 2024 VS 2031
Figure 8. Cancer Case Studies
Figure 9. Haemophilia Case Studies
Figure 10. Other Non-Cancer Diseases Case Studies
Figure 11. Next Generation Antibody Therapeutics Report Years Considered
Figure 12. Global Next Generation Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Next Generation Antibody Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Next Generation Antibody Therapeutics Market Share by Region: 2024 VS 2031
Figure 15. Global Next Generation Antibody Therapeutics Market Share by Players in 2024
Figure 16. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 2024
Figure 18. North America Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 20. United States Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 24. Germany Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Region (2020-2031)
Figure 32. China Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 40. Mexico Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Country (2020-2031)
Figure 44. Turkey Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Next Generation Antibody Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Roche Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 48. Amgen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 49. Pfizer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 50. Takeda Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 51. Daiichi Sankyo Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 52. Seagen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 53. Astellas Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 54. Immunomedics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 55. GSK Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 56. Immunocore Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 57. ADC Therapeutics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232